This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Welcome to the new home for Guidelines

Summary for secondary care

Prostate Cancer: Quality Standard


This specialist Guidelines summary covers statements on the management of prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement. The quality standard does not cover recognising and referring for suspected cancer in primary care, which is covered by NICE’s quality standard on suspected cancer.

This summary is for use by oncology teams. For information on rationales and quality measures, refer to the original quality standard (QS91) from NICE.

List of Quality Statements

Quality Statement 1: Discussion With a Named Nurse Specialist

  • People with prostate cancer have a discussion about treatment options and adverse effects with a named nurse specialist.

Quality Statement 2: Treatment Options

  • People with Cambridge Prognostic Group (CPG) 1 localised prostate cancer for whom radical treatment is suitable are offered active surveillance.
Healthcare professionals ensure that they discuss the benefits and harms of active surveillance with, and offer it to, people with CPG 1 localised prostate cancer for whom radical treatment is suitable. If active surveillance is not suitable or acceptable, they consider radical prostatectomy or radical radiotherapy.

Quality Statement 3: Combination Therapy

  • People with CPG 2, 3, 4 and 5 localised or locally advanced prostate cancer who are offered non-surgical radical treatment are offered radical radiotherapy and androgen deprivation therapy in combination.

Quality Statement 4: Managing Adverse Effects of Treatment

  • People with adverse effects of prostate cancer treatment are referred to specialist services.

Quality Statement 5: Hormone-relapsed Metastatic Prostate Cancer

  • People with hormone-relapsed metastatic prostate cancer have their treatment options discussed by the urological cancer multidisciplinary team.